A novel stapled peptide called PATAS triggered insulin-independent glucose absorption in fat cells and reversed insulin resistance, glucose intolerance, and liver disease in rodent models.
First-in-class mechanismPATAS is the first therapeutic peptide to target the ALMS1-PKCα interaction in fat cells, enabling insulin-independent glucose absorption — a completely new approach to treating insulin resistance.
What the researchers found
PATAS is a stapled peptide derived from the kinase domain of PKCα that disrupts the ALMS1-PKCα protein interaction in adipocytes. The mechanistic pathway was identified through studying Alström syndrome, an ultrarare genetic disorder caused by ALMS1 inactivation that results in severe insulin resistance.
In cultured human adipocytes, PATAS triggered insulin-independent glucose absorption, de novo lipogenesis (fat synthesis from glucose), and cellular glucose utilization — effectively bypassing the insulin signaling pathway.
In vivo in rodent models, PATAS reduced whole-body insulin resistance and improved glucose intolerance, fasting glucose levels, liver steatosis (fatty liver), and liver fibrosis. Importantly, the study also showed that reactivating ALMS1 specifically in adipocytes reversed all these metabolic phenotypes, confirming that the adipocyte is the key therapeutic target.
Why it matters
Current diabetes drugs primarily work by increasing insulin production or sensitivity through known pathways. PATAS represents a completely new approach — it bypasses insulin signaling entirely by targeting a previously unknown mechanism in fat cells. If it works in humans, it could help patients with severe insulin resistance who don't respond well to existing therapies, and its effects on liver steatosis and fibrosis suggest broader metabolic benefits beyond blood sugar control.
How the study worked
The researchers first identified the ALMS1-PKCα protein interaction in adipocytes through genetic studies of Alström syndrome. They screened α-helices in the PKCα kinase domain to find a peptide sequence that disrupted this interaction, then created a stapled (chemically stabilized) version called PATAS. The peptide was tested in vitro on cultured human adipocytes measuring glucose absorption, lipogenesis, and glucose utilization. In vivo testing in rodent models measured insulin resistance, glucose tolerance, fasting glucose, and liver histopathology.
What this study cannot tell us
All in vivo results are from rodent models, which may not translate to humans. The abstract does not report specific quantitative improvements (fold-changes, percentages) for the metabolic endpoints. Long-term safety, dosing optimization, and pharmacokinetics in humans are unknown. The stapled peptide's stability, bioavailability, and manufacturing scalability are not discussed. As a first-in-class compound, no clinical trial data exist.
How to read the evidence
This is a preclinical study with both in vitro (human adipocytes) and in vivo (rodent) data published in Diabetes, a top-tier journal. The mechanistic rationale is strong, backed by genetic validation through Alström syndrome studies, but no human clinical data exist yet.
When this study was published
Published in 2022, this represents relatively recent preclinical research. As a first-in-class peptide, the timeline from publication to potential clinical trials may span several years.
The bigger picture
This study emerged from rare disease research (Alström syndrome) and demonstrates how studying genetic disorders can reveal new drug targets for common diseases like type 2 diabetes. The idea that a single peptide targeting fat cells can simultaneously improve insulin resistance, glucose control, and liver disease addresses the interconnected nature of metabolic syndrome. PATAS joins a growing field of peptide therapeutics that includes GLP-1 agonists but works through an entirely different mechanism.
Questions still open
- How does PATAS compare to GLP-1 receptor agonists in terms of metabolic improvement, and could they work synergistically?
- What is the safety profile of chronically bypassing insulin signaling for glucose uptake in adipocytes?
- Is PATAS effective in human patients with common type 2 diabetes, not just in models mimicking Alström syndrome?
Common questions
How is PATAS different from drugs like semaglutide for diabetes?
What is a stapled peptide?
Read the original research
PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo.
Diabetes, 71(9), 2034-2047
Citation
Schreyer, Edwige; Obringer, Cathy; Messaddeq, Nadia; Kieffer, Bruno; Zimmet, Paul; Fleming, Alexander; Geberhiwot, Tarekegn; Marion, Vincent. (2022). PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo.. Diabetes, 71(9), 2034-2047. https://doi.org/10.2337/db22-0058